Status:
COMPLETED
The Effects of Mycophenolate Mofetil (MMF) on Renal Outcomes in Advanced Immunoglobulin A (IgA) Nephropathy Patients
Lead Sponsor:
Fan Fan Hou
Conditions:
IgA Nephropathy
Eligibility:
All Genders
16-70 years
Phase:
NA
Brief Summary
The study is to evaluate the effect of Mycophenolate Mofetil compared with losartan alone on time to doubling of serum creatinine or the onset of end stage renal disease in patients with advanced IgA ...
Eligibility Criteria
Inclusion
- Biopsy-proven primary IgA nephropathy with urinary proteinuria excretion over 1g/24 hour,subjects must meet 2 of the following criteria:
- global glomerular sclerosis plus focal segmental glomerular sclerosis ratio ≥50%
- eGFR 30 to 60 ml/min
- Hypertension (blood pressure over 140/90 mmHg or taking antihypertensive drugs)
Exclusion
- Secondary IgA nephropathy
- Familial IgA nephropathy
- Concomitant disease: cancer, infection, diabetes mellitus, connective tissue disease, abnormal liver function
- Pregnancy or breasting
- Inability to comply with study and follow-up procedures
Key Trial Info
Start Date :
July 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2022
Estimated Enrollment :
238 Patients enrolled
Trial Details
Trial ID
NCT01854814
Start Date
July 1 2013
End Date
May 1 2022
Last Update
July 11 2022
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Nanfang Hospital Southern Medical University
Guangzhou, Guangdong, China, 510515
2
The Fourth People's Hospital Shenzhen
Shenzhen, Guangdong, China, 518000
3
The Institute of Nephrology, Guangdong Medical College
Zhanjiang, Guangdong, China, 524001